CytoMed Therapeutics Limited (GDTC) has released an update.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
CytoMed Therapeutics Limited has released its unaudited interim condensed consolidated financial statements for the six months ended June 30, 2023 and 2024, revealing a loss for the period. The company experienced a decrease in total comprehensive loss from S$2,224,461 in 2023 to S$1,083,150 in 2024, with corresponding losses per share of S$0.22 and S$0.09 respectively. Key financial figures include research expenses and other operating losses, alongside revenue and operating income data for the concerned periods.
For further insights into GDTC stock, check out TipRanks’ Stock Analysis page.
